Predicting risk of cardiovascular events 1 to 3 years post‐myocardial infarction using a global registry
Stuart Pocock(London School of Hygiene & Tropical Medicine), Mauricio G. Cohen(Santa Ana College), Satoshi Yasuda(Tohoku University), John Gregson(London School of Hygiene & Tropical Medicine), Karolina Andersson Sundell(AstraZeneca (Brazil)), Katarina Hedman(AstraZeneca (Brazil)), David Brieger(The University of Sydney), Ji Y. Chen(Guangdong General Hospital), Dirk Westermann(University Medical Center Freiburg), Kirsten L. Rennie(University of London), Richard Grieve(MRC Clinical Trials Unit at UCL), Tabassome Simon(Sorbonne Université), Christopher B. Granger(Clinical Research Institute), José Carlos Nicolau(Hospital São Paulo), Shaun G. Goodman(St. Michael's Hospital)
Cited by 28
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k